Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gel could speed healing of stubborn leg wounds

NCT ID NCT06707090

Disease control Sponsor: TR Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether a gel called TR987, applied to the skin, can help heal chronic leg ulcers caused by poor blood flow. About 312 adults with venous leg ulcers will receive either the gel plus standard wound care or standard care alone. The main goal is to see if the gel leads to complete wound closure within 16 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TR987 0.1% gel
What this could lead to
If successful, this gel could become a new treatment option to help heal stubborn leg ulcers faster and reduce pain.
What could go wrong
This is a Phase 3 trial, so results are not yet proven. The gel may not work better than standard care alone, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 312 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 18 years and older * Venous insufficiency has been clinically diagnosed clinically and medically confirmed. * Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control. * The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization. * Target ulcer age must be ≥ 4 weeks at Screening. * Participants must have adequate arterial flow as confirmed by ABI/TBI, TB, SPP, TCPo2, or Duplex Doppler. * Body mass index (BMI) ≤ 50 kg/m2. * HbA1C ≤12%. Exclusion Criteria: * Target ulcer has been treated with prohibited medications or therapies. * History of radiation at the target ulcer site. * Target ulcer decreases in area by 30% or more during screening period. * History of osteomyelitis at the target ulcer within 6 months of screening. * Participants considered nutritionally deficient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-healing wound are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic ulcer of skin chronic venous insufficiency injury ulcer of lower limbs Varicose Ulcer venous insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-healing wound Venous insufficiency of leg Venous leg ulcer Venous stasis Venous stasis ulcer Venous ulcer Wound heal Wounds

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    27 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clincial Research Site 01

    RECRUITING

    Lafayette, Louisiana, 70507, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 02

    RECRUITING

    McComb, Mississippi, 39648, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 04

    RECRUITING

    Bossier City, Louisiana, 71111, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 07

    RECRUITING

    D'Iberville, Mississippi, 39540, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 10

    RECRUITING

    O'Fallon, Illinois, 62269, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 11

    RECRUITING

    Los Angeles, California, 90063, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 13

    RECRUITING

    Pembrook Pines, Florida, 33026, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 14

    RECRUITING

    Fresno, California, 93710, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 18

    RECRUITING

    Suffolk, Virginia, 23434, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 19

    RECRUITING

    Miami, Florida, 33150, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 21

    ACTIVE_NOT_RECRUITING

    Tucson, Arizona, 85715, United States

  • Clincial Research Site 22

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611, United States

  • Clincial Research Site 23

    WITHDRAWN

    Mentor, Ohio, 44060, United States

  • Clincial Research Site 24

    RECRUITING

    Fort Worth, Texas, 76104, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 26

    RECRUITING

    Miami, Florida, 33156, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 28

    RECRUITING

    Tulsa, Oklahoma, 74137, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 30

    RECRUITING

    New York, New York, 10019, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 32

    RECRUITING

    Houston, Texas, 27707, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 34

    RECRUITING

    Chicago, Illinois, 60649, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 36

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 37

    RECRUITING

    Syosset, New York, 11791, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 38

    NOT_YET_RECRUITING

    Hollywood, Florida, 33021, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 40

    RECRUITING

    Jacksonville, Florida, 32209, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 43A

    RECRUITING

    San Francisco, California, 94115, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 43B

    RECRUITING

    San Francisco, California, 94117, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 43C

    RECRUITING

    Castro Valley, California, 94546, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 45

    WITHDRAWN

    Grove City, Ohio, 43123, United States

  • Clincial Research Site 46

    NOT_YET_RECRUITING

    San Antonio, Texas, 78224, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 47

    ACTIVE_NOT_RECRUITING

    Deerfield Beach, Florida, 33442, United States

  • Clincial Research Site 49

    RECRUITING

    Springfield, Illinois, 62704, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 51

    WITHDRAWN

    Tamarac, Florida, 33321, United States

  • Clincial Research Site 54

    RECRUITING

    Vista, California, 92081, United States

    Contact Email: •••••@•••••

  • Clincial Research Site 55

    ACTIVE_NOT_RECRUITING

    Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.